Governance

Douglas Bryant, Chairman and Chief Executive Officer of QuidelOrtho Corporation, designs the company’s long-term vision and strategy.

Mr. Bryant has more than three decades of industry experience, undertaking multiple global leadership roles in the diagnostics space.

Mr. Bryant served as President and Chief Executive Officer of Quidel Corp. from March 2009 to May 2022, where he orchestrated the company’s transformative response to the COVID-19 pandemic and complementary acquisition of Ortho Clinical Diagnostics. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations.

From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories, including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations, and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations in the Asia Pacific.

Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

Robert Bujarski, President and Chief Operating Officer of QuidelOrtho Corporation, leads implementation of the company’s strategy and strengthens operational performance.

Mr. Bujarski has over two decades of enterprise experience spanning the full spectrum of operational, commercial, and legal functions within the diagnostics sector.

Mr. Bujarski was the Chief Operating Officer of Quidel Corp. from September 2020 to May 2022, where he architected expansions of the company’s scope and scale and facilitated the seamless integration of Quidel Corp. and Ortho Clinical Diagnostics.

Previously, Mr. Bujarski was Quidel’s Senior Vice President for North America Commercial Operations from July 2019 to September 2020, Senior Vice President, General Counsel from March 2007 to September 2020, Senior Vice President, Business Development from August 2009 to July 2019, and General Counsel and Vice President from July 2005 to March 2007. Prior to joining Quidel, Mr. Bujarski was an associate attorney with the law firm of Gibson, Dunn & Crutcher LLP in its transactions practice group from October 2001 to July 2005.

Mr. Bujarski received his B.A. and J.D. from the University of Arizona.

Joseph Busky, Chief Financial Officer of QuidelOrtho Corporation, manages global finance and drives value creation to enable growth and long-term success.

Mr. Busky has more than 30 years of experience in corporate and operational finance for large, global companies across diagnostics, medical devices, telecom, and marketing services. He has worked both for publicly owned companies and within private equity-owned settings.

Prior to joining Ortho Clinical Diagnostics in July 2020, Mr. Busky served as Chief Financial Officer for Vyaire Medical, Inc., a global medical device company. Before Vyaire, Mr. Busky was Chief Financial Officer of FDH Velocitel, an engineering services company in the telecom space. Previously, he served seven years as Chief Financial Officer of InnerWorkings, Inc., a global marketing services firm with operations in 33 countries, and held corporate and divisional finance roles for a combined 11 years at Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc., Bayer Diagnostics and Diagnostic Products Corporation, including serving as Chief Accounting Officer at Dade Behring.

Mr. Busky holds an MBA with a finance concentration, as well as a BBA in Accounting, from Loyola University in Baltimore. He also holds a CPA certification in Maryland from the American Institute of Certified Public Accountants.

Michael Iskra, Chief Commercial Officer of QuidelOrtho Corporation, leads the development and implementation of the company’s integrated global commercial strategy for accelerated growth.

Mr. Iskra has more than 25 years of experience in sales, marketing, operations, and general management in diagnostics and health care products and services.

Mr. Iskra was the Executive Vice President of Commercial Excellence and Strategy at Ortho Clinical Diagnostics from 2020 to 2022. Before assuming the role, Mr. Iskra was Ortho’s President of North America commercial operations, leading the company’s North America customer-facing organization, spanning sales, service, and regional marketing, as well as regional commercial support functions.

Prior to Ortho, he served as Senior Vice President of Business Development for Healthways. He previously was the general manager of a newly acquired business at CCS Medical and spent 14 years at Bayer/Siemens Diagnostics in a variety of roles with increasing responsibility.

Mr. Iskra holds a B.A. in International Relations from the University of Delaware. He also completed the Executive Management Program at the University of Notre Dame, Mendoza College of Business, and the General Management Leadership Program at Columbia Business School.

Michelle Hodges, General Counsel of QuidelOrtho Corporation, heads the legal and compliance group, supporting the company’s global business, and oversees all legal and governance matters affecting the company.

Ms. Hodges has over two decades of professional legal experience, specializing in advising public and private companies on mergers and acquisitions, strategic investments, securities law, and corporate governance.

Ms. Hodges served as Senior Vice President, General Counsel of Quidel Corp. from December 2020 to May 2022. Prior to joining Quidel, Ms. Hodges was a corporate lawyer with the international law firm of Gibson, Dunn & Crutcher LLP from December 1996 through November 2020, serving as a Partner of the firm for 16 years.

Ms. Hodges earned her J.D. and MBA from the University of California, Los Angeles. She earned a Bachelor of Horticultural Science degree with honors from Massey University, New Zealand.

Dr. Werner Kroll, Senior Vice President, Research & Development of QuidelOrtho Corporation, oversees R&D innovation for the company’s immunoassay and molecular products, leading groundbreaking developments from initial concept to manufacturability with the goal of improving human health globally.

Dr. Kroll has over three decades of industry experience, holding multiple leadership positions in research and development for major companies in the diagnostics space.

Dr. Kroll served as Senior Vice President, Research & Development of Quidel Corp. from 2014 to 2022, where he facilitated the development of countless industry-defining immunoassay and molecular products. Prior to joining Quidel, Dr. Kroll was Vice President and Global Head of Research and Innovation for Novartis Molecular Diagnostics/Codiagnostics. He has also held senior positions at Novartis Pharmaceuticals, Bayer Diagnostics, Bayer Pharmaceuticals, and AGFA. In addition, Dr. Kroll serves on the board of directors of the European Personalised Medicine Association (EPEMED).

Dr. Kroll received his Ph.D. in Physiological Chemistry from the University of Marburg.